目的:结直肠癌(CRC)的治疗管理尚未产生有希望的长期结果。因此,有必要进一步研究可能的治疗方案.各种实验研究了芹菜素对CRC的影响,并显示出相互矛盾的结果。本系统综述和荟萃分析调查了当前关于芹菜素对CRC影响的现有证据。
方法:Medline,Embase,Scopus,和WebofScience数据库中检索了与芹菜素及其在临床前环境中对CRC的影响相关的文章。细胞活力,生长抑制,凋亡,和体外细胞周期停滞,和体重,肿瘤大小,并提取体内研究中的死亡率作为结果。
结果:本荟萃分析纳入了39篇研究结直肠腺癌的文章。这些研究中有37项具有体外实验的数据,有8项研究有体内实验数据。六篇文章进行了体外和体内评估。我们的分析显示芹菜素降低细胞活力并诱导生长抑制,凋亡,和体外研究中的细胞周期阻滞。少数体内研究表明芹菜素可减小肿瘤大小,同时对动物结肠直肠腺癌模型的体重没有影响。
结论:我们的结果表明芹菜素,通过降低细胞活力,诱导生长抑制,凋亡,和细胞周期停滞,通过减小肿瘤大小,可以被认为是治疗结直肠腺癌的可能的佐剂。然而,在将现有证据转化为临床研究之前,还需要进一步的体内研究.
OBJECTIVE: Therapeutic management of colorectal cancer (CRC) does not yet yield promising long-term results. Therefore, there is a need for further investigation of possible therapeutic options. Various experiments have studied the effects of apigenin on CRC and have shown conflicting results. This systematic review and meta-analysis investigates the currently existing evidence on the effect of apigenin on CRC.
METHODS: Medline, Embase, Scopus, and Web of Science databases were searched for articles related to apigenin and its effect on CRC in the preclinical setting. Cell viability, growth inhibition, apoptosis, and cell cycle arrest for in-vitro, and body weight, tumor size, and mortality in in-vivo studies were extracted as outcomes.
RESULTS: Thirty-nine articles investigating colorectal adenocarcinoma were included in this meta-analysis. Thirty-seven of these studies had data for in vitro experiments, with eight studies having data for in vivo experiments. Six articles had both in vitro and in vivo assessments. Our analysis showed apigenin reduces cell viability and induces growth inhibition, apoptosis, and cell cycle arrest in in vitro studies. The few in vivo studies indicate that apigenin decreases tumor size while showing no effects on the body weight of animal colorectal adenocarcinoma models.
CONCLUSIONS: Our results demonstrated that apigenin, through reducing cell viability, inducing growth inhibition, apoptosis, and cell cycle arrest, and also by decreasing the tumor size, can be considered as a possible adjuvant agent in the management of colorectal adenocarcinoma. However, further in vivo studies are needed before any efforts to translate the current evidence into clinical studies.